Safety of rituximab in the treatment of B cell malignancies: Implications for rheumatoid arthritis

Arthritis Research and Therapy

Volumn 5, Issue SUPPL. 4, 2003, Pages

  Hainsworth, John D ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

B cell depletion; Oncology; Rheumatoid arthritis; Rituximab; Safety

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; METHOTREXATE; MONOCLONAL ANTIBODY; PARACETAMOL; PLACEBO; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; ANEMIA; ANGIONEUROTIC EDEMA; ASTHENIA; B LYMPHOCYTE; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; CLINICAL TRIAL; COUGHING; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; DYSPNEA; EXPERIENCE; FEBRILE NEUTROPENIA; FEVER; FLUSHING; FREQUENCY ANALYSIS; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; LYMPHOCYTE DEPLETION; NAUSEA; ONCOLOGY; PAIN; PHARYNX DISEASE; PNEUMONIA; PRURITUS; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RIGOR; SIDE EFFECT; SKIN DISEASE; TUMOR LYSIS SYNDROME; URINARY TRACT INFECTION; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CLINICAL TRIALS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, NON-HODGKIN;

EID: 1242285498     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63:803-843.
2. Kim HJ, Berek C: B cells in rheumatoid arthritis. Arthritis Res 2000, 2:126-131.
3. Zhang Z, Bridges SL Jr: Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am 2001, 27: 335-353.
4. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001, 40:205-211.
5. Leandro MJ, Edwards JC and Cambridge G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002, 61:883-888.
6. Stahl H-D, Szczepaæski L, Szechiæski J, Filipowicz-Sosnowska A, Edwards JCW, Close DR, Stevens RM, Shaw TM: Rituximab in RA: efficacy and safety from a randomised, controlled trial [abstract]. Ann Rheum Dis 2003, Suppl 1:65.
7. Roche Products Ltd: Prescribing Information: Mab Thera. Welwyn Garden City, UK: Roche; 21 March 2002.
8. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999, 10:655-661.
9. Ghielmini M, Schmitz SFH, Cogliatti S, Pichert G, Fey M, Betticher D, Martinelli G, Peccatori F, Hess U, Stahel R, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi, Vorobiof D, CernyT: Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial [abstract]. Blood 2002, 100:604a.
10. Hainsworth JD, Litchy S, Burris HA III, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:4261-4267.
11. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19: 2165-2170.
12. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2163-2164.
13. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16: 2825-2833.
14. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92: 1927-1932.
15. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A, Solal-Celigny P: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101-106.
16. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999,17:1851-1857.
17. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317-324.
18. Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD III, Richards P, Greco FA: Rituximab monoclonal antibody as initial systemic therapy for patients with lowgrade non-Hodgkin lymphoma. Blood 2000, 95:3052-3056.
19. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco GA: Single agent rituximab as first-line and maintenance therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003, 21:1746-1751.
20. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ: Rituximab in indolent lymphoma: the single agent pivotal trial. Semin Oncol 1999, Suppl 14:79-87.
21. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M: Rituximab: ongoing and future clinical development. Semin Oncol 2002, Suppl 2:105-112.
22. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R: Rituximab anti-CD20 monoclonal antibody therapy in nonHodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135-3143.
23. Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Stahl H-D, Edwards JCW, Close DR, Stevens RM, Shaw TM: Infusions of rituximab in patients with rheumatoid arthritis are well tolerated [abstract]. Ann Rheum Dis 2003, Suppl 1:171.
24. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2138 (Rituximab) antiCD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90: 2188-2195.
25. Szechiński J, Szczepański L, Filipowicz-Sosnowska A, Stahl H-D, Edwards JCW, Close DR, Stevens RM, Shaw TM: Treatment of RA with rituximab leads to selective peripheral B-cell depletion with minimal effect on immunoglobulins [abstract]. Ann Rheum Dis 2003, Suppl 1:172.
26. Czuczman MS: Immunochemotherapy in indolent nonHodgkin's lymphoma. Semin Oncol 2002, Suppl 6:11-17.
27. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001, 19:389-397.
28. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA: Randomised phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: results from Cancer and Leukaemia Group B 9712 (CALGB 9712). Blood 2003, 101:6-14.
29. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse largeB-cell lymphoma. N Engl J Med 2002, 346:235-242.
30. Roche Registration Ltd: Summary of Product Characteristics: MabThera. Welwyn Garden City, UK: Roche; 2 June 1998 (revised 15 July).